Abstract
Purpose
Ki-67, tumor proliferation marker, is an important prognostic factor in a variety of cancers. In the present study, we investigated the expression and the prognostic value of Ki-67 in nephroblastoma.
Methods
Ki-67 expressions were investigated by immunohistochemistry on paraffin-embedded material in 48 children operated on because of nephroblastoma. Patients were treated according to SIOP protocol. The mean follow-up period was 5.4 years. A proliferation index was obtained by immunohistochemistry using anti-Ki-67 anti-body.
Results
The mean Ki-67 proliferation index in the blastemal type was 12.3%, and in the epithelial type, 21.4%. In the anaplastic type, Ki-67 proliferation index was: in the blastemal component 20%, in the stromal 21%, and in the epithelial 31%. In the mixed tumor type, Ki-67 proliferation index was assessed as: in the blastemal component 10%, in the epithelial 33% and in the stromal 31.5%. Proliferation index for the epithelium was significantly higher than those found for the blastema (P = 0.001). A correlation between Ki-67 and tumor stage found proliferation index significantly higher in stages I and II (P = 0.002).
Conclusion
The results support the conclusion that Ki-67 is a relevant marker for assessing the proliferative activity and tumor cell dynamics of nephroblastoma, but it may not be a good clinical prognostic marker.
Similar content being viewed by others
References
Breslow NE, Beckwith JB, Perlman EJ, Reeve AE (2006) Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor. Pediatr Blood Cancer 47:260–267
Owens CM, Brisse HJ, Olsen OE, Begent J, Smets AM (2008) Bilateral disease and new trends in Wilms tumour. Pediatr Radiol 38:30–39
Davidoff AM, Giel DW, Jones DP, Jenkins JJ, Krasin MJ, Hoffer FA, Williams MA, Dome JS (2008) The feasibility, outcome of nephron-sparing surgery for children with bilateral Wilms tumor. The St Jude Children’s Research Hospital experience 1999–2006. Cancer 112:2060–2070
Scott RH, Walker L, Olsen OE, Levitt G, Kenney I, Maher E, Owens CM, Pritchard-Jones K, Craft A, Rahman N (2006) Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. Arch Dis Child 91:995–999
Helmy T, Sarhan O, Sarhan M, El-Baz M, Dawaba M, Ghali A (2009) Renal cell carcinoma in children: single-center experience. J Pediatr Surg 44:1750–1753
Wright KD, Green DM, Daw NC (2009) Late effects of treatment for Wilms tumor. Pediatr Hematol Oncol 26:407–413
Ghanem MA, Van der Kwast TH, Sudaryo MK, Mathoera RB, van den Heuvel MM, Al-Doray AA, Nijman RM, van Steenbrugge GJ (2004) MIB-1 (Ki-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma. Clin Cancer Res 10:591–597
Bubán T, Schmidt M, Broll R, Antal-Szalmás P, Duchrow M (2004) Detection of mutations in the cDNA of the proliferation marker Ki-67 protein in four tumor cell lines. Cancer Genet Cytogenet 149:81–84
Roa EI, Elorza DX, Lantadilla HS, Ibacache SG, de Aretxabala UX (2009) Immunohistochemical expression of Ki-67 as a marker of proliferation in gallbladder mucosa samples with or without cancer. Rev Med Chil 137:881–887
Motta Rda R, Zettler CG, Cambruzzi E, Jotz GP, Berni RB (2009) Ki-67 and p53 correlation prognostic value in squamous cell carcinomas of the oral cavity and tongue. Braz J Otorhinolaryngol 75:544–549
Muñoz E, Gómez F, Paz JI, Casado I, Silva JM, Corcuera MT, Alonso MJ (2003) Ki-67 immunolabeling in pre-malignant lesions and carcinoma of the prostate Histological correlation and prognostic evaluation. Eur J Histochem 47:123–128
Ancuţa E, Ancuţa C, Cozma LG, Iordache C, Anghelache-Lupaşcu I, Anton E, Carasevici E, Chirieac R (2009) Tumor biomarkers in cervical cancer: focus on Ki-67 proliferation factor and E-cadherin expression. Rom J Morphol Embryol 50:413–418
Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M (2009) Ki-67 in pituitary neoplasms: a review. Neurosurgery 65:429–437
Koohdani F, Sasani F, Mohammad K, Mehdipour P (2009) Comparison of Ki-67 antigen expression and K-ras mutation in lung tumours induced by urethane in mice. Singapore Med J 50:729–733
Krsková L, Kalinová M, Brízová H, Mrhalová M, Sumerauer D, Kodet R (2009) Molecular immunohistochemical analyses of BCL2, KI-67, cyclin D1 expression in synovial sarcoma. Cancer Genet Cytogenet 193:1–8
Diop S, Letestu R, Orsolani D, Leboeuf Y, Le Tutour P, Thiam D, Diakhate L, Valensi F (2005) Expression of proliferation marker Ki 67 in chronic lymphocytic leukemia. Dakar Med 50:65–68
Rodrigues RB, Motta Rda R, Machado SM, Cambruzzi E, Zettler EW, Zettler CG, Jotz GP (2008) Prognostic value of the immunohistochemistry correlation of Ki-67 and p53 in squamous cell carcinomas of the larynx. Braz J Otorhinolaryngol 74:855–859
Neves LR, Oshima CT, Artigiani-Neto R, Yanaguibashi G, Lourenço LG, Forones NM (2009) Ki67 and p53 in gastrointestinal stromal tumors - GIST. Arq Gastroenterol 46:116–120
Oshima CT, Iriya K, Forones NM (2005) Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma 52:420–424
de Azambuja E, Cardoso F, de Castro G, Colozza M Jr, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96:1504–1513
Tzanakis NE, Peros G, Karakitsos P, Giannopoulos GA, Efstathiou SP, Rallis G, Tsigris C, Kostakis A, Nikiteas NI (2009) Prognostic Significance of p53 and Ki67 Proteins Expression in Greek Gastric Cancer Patients. Acta Chir Belg 109:606–611
Zils K, Furtwängler R, Reinhard H, Alkassar M, Graf N (2008) Consultation within the nephroblastoma trial SIOP 2001/GPOH as part of the workload in the trial office. Klin Padiatr 220:183–188
Berrebi D, Leclerc J, Schleiermacher G, Zaccaria I, Boccon-Gibod L, Fabre M, Jaubert F, El Ghoneimi A, Jeanpierre C, Peuchmaur M (2008) High cyclin E staining index in blastemal, stromal or epithelial cells is correlated with tumor aggressiveness in patients with nephroblastoma. PLoS One 3:e2216
de Kraker J, Jones KP (2005) Treatment of Wilms tumor: an international perspective. J Clin Oncol 23:3156–3157
Metzger ML, Dome JS (2005) Current therapy for Wilms’ tumor. Oncologist 10:815–826
Boccon-Gibod L (1998) Pathological evaluation of renal tumors in children: International Society of Pediatric Oncology approach. Pediatr Dev Pathol 1:243–248
Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322
Kayaselçuk F, Zorludemir S, Gümürdühü D, Zeren H, Erman T (2002) PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade. J Neurooncol 57:115–121
Culić S, de Kraker J, Kuljis D, Kuzmić I, Saraga M, Culić V, Balarin L, Primorac D (1998) Fatal hepatic veno-occlusive disease with fibrinolysis as the cause of death during preoperative chemotherapy for nephroblastoma. Med Pediatr Oncol 31:175–176
Delahunt B, Farrant GJ, Bethwaite PB, Nacey JN, Lewis ME (1994) Assessment of proliferative activity in Wilms’ tumor. Anal Cell Pathol 7:127–138
Khine MM, Aung W, Sibbons PD, Howard CV, Clapham E, McGill F, VeilzenD Van (1994) Analysis of relative proliferation rates of Wilms’ tumor components using proliferating cell nuclear antigen and MIBI-1 (Ki-67 equivalent antigen) immunostaining and assessment of mitotic index. Lab Invest 70:125–129
Keshgegian AA, Johnston E, Canaan A (1998) Bc-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 110:443–449
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jurić, I., Pogorelić, Z., Kuzmić-Prusac, I. et al. Expression and prognostic value of the Ki-67 in Wilms’ tumor: experience with 48 cases. Pediatr Surg Int 26, 487–493 (2010). https://doi.org/10.1007/s00383-010-2588-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00383-010-2588-3